Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania

Current Medical Research and Opinion
Lizheng ShiMauricio Tohen

Abstract

This study analyzed the effect of olanzapine on a psychopathology-based scale assessing abnormal thought processes and examined the relationship between improvement on this scale and mania and depression improvement in acutely manic patients. The study sample (N = 254) was pooled from two double-blind, randomized, placebo-controlled clinical trials. Disturbance in thought processes was measured by the Positive and Negative Symptom Scale cognitive component (PANSS-Cognitive) score. Mood severity was measured by the Young-Mania Rating Scale (Y-MRS) and Hamilton Depression Inventory (HAM-D). Last-observation-carried-forward (LOCF) changes from baseline to endpoint (Week 3) were presented for patients who had at least one post-baseline assessment. Olanzapine-treated patients experienced modest but significant improvement in PANSS-Cognitive score (olanzapine: -4.25 n = 124; placebo: -1.69 n = 120, p < 01), regardless of age, gender, mania subtype (pure, mixed), course (rapid or non-rapid cycling), or the presence or absence of psychotic features. PANSS-Cognitive improvement was more highly correlated with mania than depression improvement. Olanzapine improved abnormal thought processes measured by the PANSS-Cognitive score in patien...Continue Reading

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1990·Schizophrenia Bulletin·S R Kay, S Sevy
Feb 1, 1995·Schizophrenia Research·J P LindenmayerR B Hyman
Jan 19, 1999·Archives of General Psychiatry·W G van GorpD Plotkin
Jul 31, 2001·Journal of Clinical Psychopharmacology·J P LindenmayerA Iskander
Mar 18, 2003·Journal of Clinical Psychopharmacology·Robert W BakerGary D Tollefson
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Apr 22, 2004·Schizophrenia Research·Jean-Pierre LindenmayerVirginia L Stauffer

❮ Previous
Next ❯

Citations

May 25, 2012·European Archives of Psychiatry and Clinical Neuroscience·Konstantinos N FountoulakisEduard Vieta
Nov 21, 2007·CNS Drugs·Katherine E BurdickAnil K Malhotra
Jun 15, 2005·Bipolar Disorders·Lakshmi N YathamUNKNOWN Canadian Network for Mood and Anxiety Treatments
Feb 27, 2013·Bipolar Disorders·Konstantinos N FountoulakisLakshmi N Yatham
Sep 16, 2015·CNS Drugs·Andrea FagioliniAllan H Young
May 11, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Annabel VreekerRené S Kahn
Jan 6, 2012·The International Journal of Neuropsychopharmacology·Konstantinos N FountoulakisLakshmi N Yatham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Related Papers

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület lapja = official journal of the Hungarian Association of Psychopharmacology
Thomas A Ban
Türk psikiyatri dergisi = Turkish journal of psychiatry
E Cem Atbaşoğlu, Sinan Gülöksüz
© 2021 Meta ULC. All rights reserved